Trial Profile
A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Jul 2016
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine; Lamivudine; Tenofovir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors ViiV Healthcare
- 15 Jul 2016 New trial record